Elevated Donor-Derived Cell-Free DNA Levels Are Associated With Reduced Myocardial Blood Flow but Not Angiographic Cardiac Allograft Vasculopathy: The EVIDENT Study
Authors:
- Cathrine M. MoellerCMCathrine M. Moeller
- Daniel OrenDODaniel Oren
- Gal RubinsteinGRGal Rubinstein
- Ersilia M. DeFilippisEDErsilia M. DeFilippis
- Salwa RahmanSRSalwa Rahman
- Yonatan MehlmanYMYonatan Mehlman
- Elena M. DonaldEDElena M. Donald
- Dor LotanDLDor Lotan
- Edward LinELEdward Lin
- Kyung T. OhKOKyung T. Oh
- Sun H. LeeSLSun H. Lee
- 1 January 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (1) , e011756
Abstract
BACKGROUND: Cardiac allograft vasculopathy (CAV) leads to impaired myocardial blood flow (MBF), increasing the risk of cardiovascular death or retransplant among heart transplantation (HT) recipients. Data on elevation in donor-derived cell-free DNA (dd-cfDNA) and CAV in the absence of rejection are mixed. We sought to test the hypothesis that CAV with reduced MBF (RMBF) is associated with elevated dd-cfDNA. METHODS: A retrospective review was conducted on HT recipients at a high-volume center who underwent dd-cfDNA testing between September 2019 and November 2022. Inclusion criteria included undergoing CAV screening with cardiac positron emission tomography scans and coronary angiograms. Patients were grouped by the presence of angiographic CAV diagnosis and MBF reserve evaluated through cardiac positron emission tomography. The latter was subdivided into normal MBF or RMBF, with RMBF defined as an MBF reserve ≤2. Elevated dd-cfDNA was defined as ≥0.12%. RESULTS: Two hundred fifty-six HT recipients were included (median age, 55 years; 27.6% female; median, 8 years [interquartile range (IQR), 5–14] post-HT). Ischemic etiology of heart failure was more prevalent in the RMBF group (36%) compared with the normal MBF group (20%; P =0.02). The prevalence and magnitude of a positive dd-cfDNA test with angiographic CAV (29%; median, 0.26% [IQR, 0.15%–0.62%]) were not significantly different from those without CAV (30%; P =0.94; median, 0.31% [IQR, 0.17%–0.71%]; P =0.38). However, RMBF patients exhibited significantly higher dd-cfDNA prevalence and levels (51%; median, 0.81% [IQR, 0.48%–1.11%]) compared with normal MBF patients (27%; P P <0.001). CONCLUSIONS: HT recipients with angiographic CAV had similar dd-cfDNA levels and rates as those without. Notably, dd-cfDNA levels and rates were significantly elevated in patients with RMBF assessed by positron emission tomography compared with those with normal MBF.Keywords
This publication has 12 references indexed in Scilit:
- Lack of Association Between Donor‐Derived Cell‐Free DNA and Cardiac Allograft VasculopathyClinical Transplantation, 2024
- Negative Predictive Value and Prognostic Associations of Rb-82 PET/CT with Myocardial Blood Flow in CAVJACC: Heart Failure, 2023
- Noninvasive Physiologic Assessment of Cardiac Allograft Vasculopathy Is Prognostic for Post-Transplant EventsJACC, 2022
- Microcirculatory Resistance Predicts Allograft Rejection and Cardiac Events After Heart TransplantationJACC, 2021
- Prognostic value of comprehensive intracoronary physiology assessment early after heart transplantationEuropean Heart Journal, 2021
- The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult heart transplantation report — 2021; Focus on recipient characteristicsThe Journal of Heart and Lung Transplantation, 2021
- Donor‐derived cell‐free DNA is associated with cardiac allograft vasculopathyClinical Transplantation, 2020
- Noninvasive detection of graft injury after heart transplant using donor-derived cell-free DNA: A prospective multicenter studyAmerican Journal of Transplantation, 2019
- Diagnostic and prognostic value of myocardial blood flow quantification as non-invasive indicator of cardiac allograft vasculopathyEuropean Heart Journal, 2017
- International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy—2010The Journal of Heart and Lung Transplantation, 2010